In a report released yesterday, Josh Jennings from TD Cowen maintained a Buy rating on TransMedics Group, with a price target of $190.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Josh Jennings has given his Buy rating due to a combination of factors that support a favorable growth outlook for TransMedics Group. He points to the company moving past the initial rollout phase of its Organ Care System and National OCS Program, which now more directly ties revenue growth to underlying U.S. transplant market dynamics and the ramp of TransMedics Aviation.
Jennings also highlights that early second-quarter 2026 data show year-over-year increases in liver, lung, and heart transplant procedures, with combined transplant volume still growing, albeit at a slightly slower pace than in the prior quarter. This sustained procedure growth underpins confidence in ongoing utilization of TransMedics’ platform, and supports maintaining a $190 price target, which remains unchanged.
In another report released on April 27, Canaccord Genuity also maintained a Buy rating on the stock with a $152.00 price target.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMDX in relation to earlier this year.